 Carolyn Lefkowits
Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genital Neoplasms, Female | 20 | 2023 | 82 | 7.050 |
Why?
| | Cancer Pain | 6 | 2019 | 27 | 2.910 |
Why?
| | Palliative Care | 15 | 2023 | 706 | 2.840 |
Why?
| | Analgesics, Opioid | 7 | 2021 | 925 | 1.990 |
Why?
| | Pain Management | 5 | 2021 | 334 | 1.650 |
Why?
| | Medical Oncology | 8 | 2022 | 268 | 1.460 |
Why?
| | Surgical Oncology | 3 | 2019 | 22 | 1.380 |
Why?
| | Gynecology | 7 | 2020 | 174 | 1.310 |
Why?
| | Hot Flashes | 3 | 2013 | 82 | 1.150 |
Why?
| | Pain, Postoperative | 3 | 2021 | 247 | 0.830 |
Why?
| | Hospice Care | 2 | 2023 | 194 | 0.810 |
Why?
| | Terminal Care | 3 | 2023 | 216 | 0.810 |
Why?
| | Referral and Consultation | 4 | 2017 | 735 | 0.780 |
Why?
| | Opioid-Related Disorders | 5 | 2019 | 484 | 0.710 |
Why?
| | Communication | 3 | 2020 | 847 | 0.610 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1514 | 0.560 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2019 | 230 | 0.530 |
Why?
| | Attitude of Health Personnel | 3 | 2019 | 1106 | 0.520 |
Why?
| | Perinatal Care | 1 | 2016 | 55 | 0.510 |
Why?
| | Neoplasms | 2 | 2021 | 2454 | 0.490 |
Why?
| | Palliative Medicine | 1 | 2014 | 15 | 0.450 |
Why?
| | Obstetrics and Gynecology Department, Hospital | 1 | 2014 | 9 | 0.440 |
Why?
| | Oncology Service, Hospital | 1 | 2014 | 16 | 0.440 |
Why?
| | Ambulatory Care | 2 | 2017 | 509 | 0.430 |
Why?
| | Endometrial Neoplasms | 3 | 2020 | 161 | 0.420 |
Why?
| | Cyclohexanecarboxylic Acids | 1 | 2013 | 22 | 0.400 |
Why?
| | Amines | 1 | 2013 | 37 | 0.400 |
Why?
| | Cost of Illness | 1 | 2014 | 277 | 0.400 |
Why?
| | Female | 30 | 2023 | 68829 | 0.400 |
Why?
| | Oncologists | 3 | 2022 | 35 | 0.380 |
Why?
| | Needs Assessment | 1 | 2014 | 357 | 0.380 |
Why?
| | Complementary Therapies | 1 | 2013 | 87 | 0.380 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2013 | 168 | 0.370 |
Why?
| | Analgesics | 1 | 2013 | 194 | 0.360 |
Why?
| | Education, Medical, Graduate | 1 | 2014 | 443 | 0.330 |
Why?
| | Quality of Life | 6 | 2023 | 2695 | 0.330 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2022 | 72 | 0.330 |
Why?
| | Guideline Adherence | 1 | 2014 | 527 | 0.320 |
Why?
| | Humans | 33 | 2023 | 129847 | 0.320 |
Why?
| | Health Services Accessibility | 1 | 2016 | 903 | 0.320 |
Why?
| | Employment | 2 | 2021 | 167 | 0.320 |
Why?
| | Middle Aged | 16 | 2021 | 31177 | 0.300 |
Why?
| | Prostatic Neoplasms | 2 | 2013 | 999 | 0.300 |
Why?
| | Aged | 12 | 2020 | 22107 | 0.280 |
Why?
| | Epidemics | 2 | 2018 | 82 | 0.260 |
Why?
| | Advance Care Planning | 2 | 2020 | 202 | 0.240 |
Why?
| | Breast Neoplasms | 2 | 2013 | 2104 | 0.220 |
Why?
| | Medical Futility | 1 | 2023 | 23 | 0.210 |
Why?
| | Aged, 80 and over | 4 | 2020 | 7066 | 0.210 |
Why?
| | Adult | 11 | 2021 | 35634 | 0.210 |
Why?
| | Patient Care Team | 2 | 2019 | 603 | 0.200 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 57 | 0.200 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2019 | 957 | 0.190 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2013 | 155 | 0.190 |
Why?
| | Retrospective Studies | 7 | 2022 | 14553 | 0.180 |
Why?
| | Brachytherapy | 2 | 2019 | 104 | 0.180 |
Why?
| | Cohort Studies | 4 | 2021 | 5444 | 0.170 |
Why?
| | Ethics, Medical | 1 | 2020 | 78 | 0.160 |
Why?
| | Enoxaparin | 1 | 2020 | 59 | 0.160 |
Why?
| | Radiosurgery | 1 | 2022 | 321 | 0.160 |
Why?
| | Infection Control | 1 | 2020 | 143 | 0.150 |
Why?
| | Carcinoma, Endometrioid | 1 | 2019 | 44 | 0.150 |
Why?
| | Pyridones | 1 | 2020 | 158 | 0.150 |
Why?
| | Hospices | 1 | 2020 | 86 | 0.150 |
Why?
| | Carcinosarcoma | 1 | 2018 | 16 | 0.150 |
Why?
| | Postoperative Care | 1 | 2020 | 244 | 0.150 |
Why?
| | Young Adult | 5 | 2020 | 12467 | 0.140 |
Why?
| | Disease-Free Survival | 1 | 2019 | 647 | 0.140 |
Why?
| | Uterine Neoplasms | 1 | 2018 | 100 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2019 | 249 | 0.140 |
Why?
| | Preoperative Care | 1 | 2019 | 337 | 0.140 |
Why?
| | beta Catenin | 1 | 2019 | 224 | 0.140 |
Why?
| | Cancer Care Facilities | 1 | 2017 | 32 | 0.130 |
Why?
| | Perinatal Death | 1 | 2016 | 21 | 0.130 |
Why?
| | Pyrazoles | 1 | 2020 | 403 | 0.130 |
Why?
| | Survival Analysis | 1 | 2020 | 1271 | 0.130 |
Why?
| | Drug and Narcotic Control | 1 | 2016 | 28 | 0.130 |
Why?
| | Truth Disclosure | 1 | 2016 | 45 | 0.130 |
Why?
| | Life Expectancy | 1 | 2016 | 61 | 0.130 |
Why?
| | Databases, Factual | 2 | 2019 | 1269 | 0.130 |
Why?
| | Nausea | 1 | 2016 | 111 | 0.130 |
Why?
| | Venous Thromboembolism | 1 | 2020 | 287 | 0.130 |
Why?
| | Cancer Survivors | 1 | 2020 | 257 | 0.130 |
Why?
| | Mood Disorders | 1 | 2016 | 121 | 0.120 |
Why?
| | Anticoagulants | 1 | 2020 | 637 | 0.120 |
Why?
| | Self Efficacy | 1 | 2019 | 377 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 342 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 336 | 0.120 |
Why?
| | Hospitalization | 2 | 2014 | 2079 | 0.110 |
Why?
| | Program Evaluation | 1 | 2019 | 878 | 0.110 |
Why?
| | Outpatients | 2 | 2017 | 375 | 0.110 |
Why?
| | Physician-Patient Relations | 1 | 2019 | 542 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2019 | 743 | 0.110 |
Why?
| | Evidence-Based Medicine | 1 | 2018 | 716 | 0.110 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1149 | 0.110 |
Why?
| | Stellate Ganglion | 1 | 2013 | 4 | 0.100 |
Why?
| | Clonidine | 1 | 2013 | 27 | 0.100 |
Why?
| | Symptom Assessment | 1 | 2014 | 125 | 0.100 |
Why?
| | Societies, Medical | 1 | 2016 | 759 | 0.100 |
Why?
| | Anxiety | 1 | 2019 | 976 | 0.100 |
Why?
| | Ovariectomy | 1 | 2013 | 137 | 0.100 |
Why?
| | Mass Screening | 1 | 2020 | 1192 | 0.100 |
Why?
| | Nerve Block | 1 | 2013 | 68 | 0.090 |
Why?
| | Tamoxifen | 1 | 2013 | 197 | 0.090 |
Why?
| | Hormone Replacement Therapy | 1 | 2013 | 93 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1500 | 0.090 |
Why?
| | Drug Interactions | 1 | 2013 | 397 | 0.090 |
Why?
| | Continuity of Patient Care | 1 | 2014 | 277 | 0.090 |
Why?
| | Fellowships and Scholarships | 1 | 2014 | 279 | 0.090 |
Why?
| | Ovarian Neoplasms | 1 | 2016 | 482 | 0.090 |
Why?
| | Data Collection | 1 | 2014 | 653 | 0.090 |
Why?
| | Pain | 1 | 2016 | 791 | 0.090 |
Why?
| | Depression | 1 | 2019 | 1323 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1501 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1560 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2018 | 4896 | 0.080 |
Why?
| | Colorado | 1 | 2019 | 4410 | 0.080 |
Why?
| | Adolescent | 4 | 2020 | 20451 | 0.080 |
Why?
| | Logistic Models | 1 | 2014 | 1989 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2020 | 2481 | 0.080 |
Why?
| | Chemoradiotherapy | 2 | 2020 | 208 | 0.070 |
Why?
| | Quality Improvement | 1 | 2016 | 1112 | 0.070 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2019 | 208 | 0.070 |
Why?
| | Curriculum | 1 | 2014 | 928 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2739 | 0.070 |
Why?
| | United States | 3 | 2020 | 13913 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5437 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2016 | 5772 | 0.060 |
Why?
| | Neoplasm Staging | 2 | 2019 | 1282 | 0.060 |
Why?
| | Risk Factors | 2 | 2019 | 9801 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2021 | 3384 | 0.050 |
Why?
| | Cranial Irradiation | 1 | 2022 | 67 | 0.050 |
Why?
| | Health Benefit Plans, Employee | 1 | 2020 | 22 | 0.040 |
Why?
| | Unemployment | 1 | 2020 | 43 | 0.040 |
Why?
| | Resource Allocation | 1 | 2020 | 39 | 0.040 |
Why?
| | Standard of Care | 1 | 2020 | 71 | 0.040 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 33 | 0.040 |
Why?
| | DNA Polymerase II | 1 | 2019 | 38 | 0.040 |
Why?
| | Microsatellite Instability | 1 | 2019 | 38 | 0.040 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 81 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2019 | 283 | 0.040 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 159 | 0.040 |
Why?
| | SEER Program | 1 | 2018 | 202 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 252 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2018 | 377 | 0.030 |
Why?
| | Male | 2 | 2013 | 63759 | 0.030 |
Why?
| | Critical Care | 1 | 2020 | 552 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 503 | 0.030 |
Why?
| | Prognosis | 1 | 2022 | 3773 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1368 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2019 | 1119 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1161 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 1951 | 0.020 |
Why?
| | Mutation | 1 | 2019 | 3706 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3269 | 0.020 |
Why?
| | Pregnancy | 1 | 2020 | 6423 | 0.020 |
Why?
| | Prospective Studies | 1 | 2017 | 7158 | 0.010 |
Why?
|
|
Lefkowits's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|